Being Fitter May Help Your Kidneys Age More Slowly, New Study Finds
People with type 2 diabetes who stop taking GLP-1 weight-loss and diabetes drugs such as Ozempic face nearly double the risk of a heart attack, stroke or death compared with those who stay on treatment, according to a major new study.
The research, published in The Lancet Regional Health – Europe, analysed electronic medical records from more than 80,000 people with type 2 diabetes and no established heart disease, treated at 301 diabetes clinics across Italy between 2004 and 2024.
The findings are striking. People who discontinued their GLP-1 treatment had about twice the combined risk of a non-fatal heart attack, a non-fatal stroke or death from any cause compared with those who continued — 3.94 events per 100 person-years versus 1.96. Death from any cause alone was around 4.8 times higher among those who stopped, at 2.23 versus 0.48 deaths per 100 person-years.
More than six in ten of the patients in the study — 48,615 of 80,302 — had stopped their GLP-1 treatment by their last clinic visit.
The researchers, led by Antonio Ceriello of IRCCS MultiMedica in Milan, say the results suggest that long-term, persistent use of these medicines may be needed to maintain their cardiovascular benefits. GLP-1 drugs, which include semaglutide (Ozempic, Wegovy) and dulaglutide (Trulicity), have transformed the treatment of type 2 diabetes and obesity, helping people manage blood sugar, lose weight and improve several aspects of metabolic health.
But the study comes with an important caveat: it was observational, so it cannot prove that stopping the drugs directly causes the higher risk. The researchers did not know why people stopped — possible reasons include side effects, cost, or illness such as frailty or cancer — and people who stop may already have been in poorer health.
Professor Naveed Sattar, a cardiometabolic medicine expert at the University of Glasgow, echoed that caution, noting that the results should be interpreted as an association rather than proof that stopping the medication itself leads to an immediate increase in risk. The study also cannot show whether the risk after stopping is higher than it would have been if a person had never started the treatment.
The findings apply specifically to people with type 2 diabetes and no previous cardiovascular disease. They may not apply to people who use these medicines for weight loss without diabetes, and the study did not include tirzepatide (Mounjaro, Zepbound), which was not available during much of the study period.
Anyone considering stopping a GLP-1 medicine should talk to their doctor first rather than stopping on their own.
Sources: The Lancet Regional Health – Europe, MedicalXpress, The Pharmacist, News18
Photo credit: Ozempic injection pen (via Body Network)
Comments
Post a Comment